(RTTNews) - Praxis Precision Medicines, Inc. (PRAX) on Monday said the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to ulixacaltamide for the treatment of patients ...

BOSTON, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

Praxis Precision Medicines has won Food and Drug Administration breakthrough-therapy designation for its ulixacaltamide drug candidate for the treatment of patients with essential tremor. Praxis on ...

A woman who shakes so badly she sometimes cannot leave the house has said finding other people with the same condition has helped her feel less alone. Leah Brown, from Eastwood in Nottinghamshire, has ...

The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential tremor Praxis remains on track to submit ulixacaltamide NDA in ...

Praxis Precision Medicines (PRAX) is soaring to fresh multi year highs after announcing this morning that the FDA granted Breakthrough Therapy Designation (BTD) for ulixacaltamide HCl in essential ...

From corsets and foot binding to urine mouthwash and nightshade eyedrops, people went to great lengths to achieve what they ...